Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
30.25
+0.65 (2.20%)
At close: Oct 24, 2025, 4:00 PM EDT
30.20
-0.05 (-0.17%)
After-hours: Oct 24, 2025, 7:19 PM EDT
HRMY Revenue
Harmony Biosciences Holdings had revenue of $200.49M in the quarter ending June 30, 2025, with 16.01% growth. This brings the company's revenue in the last twelve months to $772.53M, up 17.74% year-over-year. In the year 2024, Harmony Biosciences Holdings had annual revenue of $714.73M with 22.80% growth.
Revenue (ttm)
$772.53M
Revenue Growth
+17.74%
P/S Ratio
2.24
Revenue / Employee
$2,882,563
Employees
268
Market Cap
1.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HRMY News
- 2 days ago - Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance - Business Wire
- 9 days ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha
- 19 days ago - Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
- 4 weeks ago - Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday - Benzinga
- 4 weeks ago - Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial - Reuters
- 4 weeks ago - Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome - Business Wire
- 5 weeks ago - 11 fast-growing small-cap stocks that could get a boost from the Fed's next move - Market Watch
- 7 weeks ago - Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha